Semaglutide is a prescription medication, marketed as Ozempic and Wegovy, that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist to manage type 2 diabetes and chronic weight management. It requires a licensed provider’s oversight due to significant risks of side effects, including gastrointestinal distress and rare but serious complications like thyroid C-cell tumors or pancreatitis, according to the U.S. Food and Drug Administration (FDA).
Clinical Indications and Mechanism of Action
Semaglutide mimics the GLP-1 hormone, which the body naturally releases after eating. By binding to GLP-1 receptors, the drug stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This process increases satiety and reduces appetite. According to the National Institutes of Health (NIH), these medications are indicated specifically for patients with type 2 diabetes or those with a body mass index (BMI) meeting specific criteria for obesity or weight-related comorbidities.
Regulatory Status and Safety Warnings
The FDA has approved semaglutide under different brand names for distinct purposes. Ozempic is approved to improve blood sugar control in adults with type 2 diabetes, while Wegovy is approved for chronic weight management in adults and children aged 12 and older with obesity or overweight status.
The FDA labels for these medications include a "Boxed Warning" regarding the risk of thyroid C-cell tumors. Clinical studies in rodents showed that semaglutide caused thyroid C-cell adenomas and carcinomas. While it remains unknown if this risk translates to humans, the manufacturer advises against using the drug in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Risks of Off-Label Use and Sourcing
Acquiring semaglutide outside of a clinical prescription—such as through friend-to-friend distribution or unregulated online pharmacies—poses substantial health risks. The FDA has issued warnings regarding "compounded" versions of the drug. Compounded drugs are not FDA-approved, meaning the agency does not review them for safety, effectiveness, or manufacturing quality.
Patients obtaining these products may receive incorrect dosages or formulations containing unknown salt forms, such as semaglutide sodium or semaglutide acetate. These salt forms have not been proven to be safe or effective, and their use may result in unpredictable absorption rates or toxic reactions.
Common Side Effects
Clinical trials have documented several frequent adverse reactions associated with GLP-1 receptor agonists. According to the Mayo Clinic, the most reported side effects include:
- Nausea and vomiting
- Diarrhea or constipation
- Abdominal pain
- Fatigue
- Headache
Serious, though less common, risks include gallbladder disease, kidney injury, and vision changes in patients with diabetic retinopathy. Any individual considering semaglutide must undergo a formal medical evaluation to determine if the benefits outweigh these potential risks. Always consult a board-certified physician to discuss whether this treatment is appropriate for your specific health profile.